Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years
Open Access
- 6 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurological Sciences
- Vol. 42 (11), 4647-4655
- https://doi.org/10.1007/s10072-021-05127-z
Abstract
Background Comparative effectiveness of natalizumab and fingolimod over a follow-up longer than 2 years has been not addressed yet. Objectives To compare the effect on no evidence of disease activity (NEDA-3) in relapsing-remitting multiple sclerosis (RRMS) patients treated with natalizumab or fingolimod for at least 4 years. Methods We included RRMS patients switched from first-line agents to natalizumab or fingolimod. Patients were propensity score (PS)-matched on a 1-to-1 basis. Percentages of patients reaching NEDA-3 status at 2 and 4 years of follow-up were compared using the chi-square test. The risk of not achieving NEDA-3 at 4 years was explored in matched samples by Cox regression models. Results We evaluated 174 PS-matched patients. Patients receiving natalizumab reached a NEDA-3 status at 2 and 4 years more frequently than those exposed to fingolimod (63% vs 44%, p=0.037; 45.7% vs 25.8%, p=0.015, respectively). Patients receiving natalizumab were at a significant lower risk of not achieving the NEDA-3 status at 4 years compared to those exposed to fingolimod (hazard ratio (95% confidence interval): 0.54 (0.36–0.80), p=0.002). Conclusions Although both medications were effective in patients non-responding to first-line agents, natalizumab seems to be superior to fingolimod in RRMS in obtaining NEDA-3 status at 4 years.Keywords
Funding Information
- Universita degli Studi di Bari Aldo Moro
This publication has 36 references indexed in Scilit:
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2011
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS studyThe Lancet Neurology, 2011
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Postmarketing evidence of disease-modifying drugs in multiple sclerosisNeurological Sciences, 2008
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006
- PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology, 2001
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Interferon beta‐lb in the treatment of multiple sclerosisNeurology, 1995